In 2023, the sales of Genito Urinary System and Sex Hormones in the UK were estimated at 756 million pounds sterling. The forecasted data for 2024 to 2028 indicates a steady but modest growth in this sector, with sales projected to grow from 758.96 million pounds sterling in 2024 to 769.9 million pounds sterling in 2028.

The year-on-year growth rate shows minimal increases: approximately 0.37% for 2025, 0.36% for 2026, 0.35% for 2027, and 0.34% for 2028. This points to a stable yet slow-growing market.

Projected trends and factors to watch for in the future include:

Innovations in drug development and personalized medicine could drive market growth.
Regulatory changes and price pressures from public health services may impact sales growth.
Demographic shifts, including an aging population, could lead to increased demand.